前列腺癌
EZH2型
表观遗传学
癌症研究
PI3K/AKT/mTOR通路
mTORC1型
癌症
生物
KEAP1型
组蛋白
前列腺
医学
癌细胞
疾病
雄激素剥夺疗法
基因敲除
酶
细胞周期检查点
磷酸化
体外
雄激素
信号转导
自噬
氧化应激
代谢途径
作者
Rhea Sahu,Miriam Enos,Swastika Sharma,Amy E. Schade,Alycia Gardner,Akiko Yoshinaga,Alexandra Indeglia,Eleanor Minogue,Songhua Hu,Kiran Kurmi,Shakchhi Joshi,Daniel R. Schmidt,Samkyu Yaffe,Van T.M. Nguyen,Fang Xie,Steven P. Balk,Matthew G. Vander Heiden,Kristian Helin,Marcia C. Haigis,Karen Cichowski
摘要
Men with advanced prostate cancer are typically treated with androgen deprivation therapy, but most ultimately develop resistance and incurable disease (e.g. castration-resistant prostate cancer (CRPC)). The majority of CRPCs overexpress the epigenetic enzyme EZH2 and harbor alterations in the PI3K pathway, providing two targetable pathways outside of AR. Here we show that EZH2 inhibitors synergize with PI3K, AKT, or mTORC1 inhibitors to kill CRPC in vitro and promote tumor regression in vivo. Strikingly, these agents trigger a catastrophic energy crisis by cooperatively suppressing glycolysis, the TCA cycle, and oxidative phosphorylation prior to cell death. EZH2 and PI3K pathway inhibitors achieve this by respectively inhibiting two key regulators of metabolism, MYC and HIF-1A, while concomitantly derepressing a pro-apoptotic stress sensor. Together, these studies reveal a promising therapeutic strategy for CRPC and demonstrate how metabolic plasticity can be fatally impaired by co-targeting upstream oncogenic nodes that converge on this important process.
科研通智能强力驱动
Strongly Powered by AbleSci AI